WASHINGTON — PhRMA has a reputation in Washington for might, for money, for scorched-earth tactics, and for fighting even the tiniest of policy changes.
The pharmaceutical industry’s lobbying arm raised hell, for example, when lawmakers asked it to cover a slightly larger share of seniors’ drug costs. It spent years refusing to concede even minimal tweaks to an obscure bill related to generic competition.